Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Cantor Fitzgerald
Federal Trade Commission
Medtronic
Dow
Covington
Novartis
Argus Health
Farmers Insurance

Generated: January 19, 2018

DrugPatentWatch Database Preview

EXCEDRIN (MIGRAINE) Drug Profile

« Back to Dashboard

Which patents cover Excedrin (migraine), and what generic alternatives are available?

Excedrin (migraine) is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There is one patent protecting this drug.

This drug has thirteen patent family members in thirteen countries.

The generic ingredient in EXCEDRIN (MIGRAINE) is acetaminophen; aspirin; caffeine. There are sixty-six drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the acetaminophen; aspirin; caffeine profile page.
Summary for EXCEDRIN (MIGRAINE)
Drug patent expirations by year for EXCEDRIN (MIGRAINE)

US Patents and Regulatory Information for EXCEDRIN (MIGRAINE)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for EXCEDRIN (MIGRAINE)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for EXCEDRIN (MIGRAINE)

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Dow
Express Scripts
US Department of Justice
Johnson and Johnson
Queensland Health
Merck
McKesson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot